Electrocardiography-based artificial intelligence predicts the upcoming future of heart failure with mildly reduced ejection fraction

基于心电图的人工智能预测射血分数轻度降低的心力衰竭的未来发展趋势

阅读:1

Abstract

BACKGROUND: Heart failure with mildly reduced ejection fraction (HFmrEF) has emerged as the predominant subtype of heart failure (HF). This study aimed to develop artificial intelligence (AI)-electrocardiography (ECG) to identify and predict the prognosis of patients with HFmrEF. METHODS: We collected 104,336 12-lead ECG datasets from April 2009 to December 2021 in a tertiary centre. The AI-ECG encompasses a novel model that combines an automatic labelling preprocessing method with a transformer architecture incorporating a triplet loss for HFmrEF analysis. RESULTS: The receiver operating characteristic analyses revealed that the area under the curve of AI-ECG for identifying all types of HF was acceptable [0.873, 95% confidence interval (CI): 0.864-0.893], while that for identifying patients with HFmrEF was relatively lower (0.824, 95% CI: 0.794-0.863) than that for those with HF with reduced ejection fraction (EF) (0.875, 95% CI: 0.844-0.912) and those with normal EF (0.870, 95% CI: 0.842-0.894). The analysis of ECG features showed significant increases in QRS duration (p = 0.001), QT interval (p = 0.045), and corrected QT interval (p = 0.041) with increasing "Severity by Euclidean distance". Following the predictability analysis with another group of 953 patients for improvements of follow-up EF in HFmrEF, the patients were grouped into three clusters based on the AI-Euclidean distance; Cluster 1 had the most severe cases and poorer outcomes than Clusters 2 (p < 0.001) and 3 (p < 0.001). CONCLUSIONS: AI-ECG presents an innovative approach for the prognostic stratification of cardiac contractility in patients with HFmrEF. In patients with HFmrEF, disease progression can be predicted using AI-ECG.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。